Celularity Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Celularity Inc. (CELU) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$16.10 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-12-06.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2024-12-06
- Celularity Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2024-09-30 was -$16.10M.
- Celularity Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2024-06-30 was -$6.49M.
- Celularity Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2024-03-31 was -$22.01M.
- Celularity Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2023-12-31 was $9.55M, a 60.93% decline year-over-year.
- Celularity Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$196.29M, a 1483.14% decline from fiscal 2022.
- Celularity Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was $14.19M.
- Celularity Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was -$100.12M.
- Celularity Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$208.23M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|
| 2024-09-30 | -$16.10M 10-Q · filed 2024-12-06 | -$22.59M derived: sum of 2 quarters · filed 2024-12-06 | -$44.60M 10-Q · filed 2024-12-06 | -$35.05M derived: sum of 4 quarters · filed 2024-12-06 | |
| 2024-06-30 | -$6.49M 10-Q · filed 2024-12-06 | -$28.50M 10-Q · filed 2024-11-07 | -$18.95M derived: sum of 3 quarters · filed 2024-12-06 | -$112.83M derived: sum of 4 quarters · filed 2024-12-06 | |
| 2024-03-31 | -$22.01M 10-Q · filed 2024-12-06 | -$12.47M derived: sum of 2 quarters · filed 2024-12-06 | -$106.34M derived: sum of 3 quarters · filed 2024-12-06 | -$154.29M derived: sum of 4 quarters · filed 2024-12-06 | |
| 2023-12-31 | $9.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | -$84.33M derived: sum of 2 quarters · filed 2024-12-06 | -$132.28M derived: sum of 3 quarters · filed 2024-12-06 | -$196.29M 10-K · filed 2024-07-30 | |
| 2023-09-30 | -$93.88M 10-Q · filed 2024-12-06 | -$141.82M derived: sum of 2 quarters · filed 2024-12-06 | -$205.84M 10-Q · filed 2024-12-06 | -$181.41M derived: sum of 4 quarters · filed 2024-12-06 | |
| 2023-06-30 | -$47.95M 10-Q · filed 2024-12-06 | -$111.97M 10-Q · filed 2024-11-07 | -$87.53M derived: sum of 3 quarters · filed 2024-12-06 | -$82.73M derived: sum of 4 quarters · filed 2024-12-06 | |
| 2023-03-31 | -$64.02M 10-Q · filed 2024-12-06 | -$39.58M derived: sum of 2 quarters · filed 2024-12-06 | -$34.78M derived: sum of 3 quarters · filed 2024-12-06 | $13.04M derived: sum of 4 quarters · filed 2024-12-06 | |
| 2022-12-31 | $24.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $29.23M derived: sum of 2 quarters · filed 2024-07-30 | $77.06M derived: sum of 3 quarters · filed 2024-07-30 | $14.19M 10-K · filed 2024-07-30 | |
| 2022-09-30 | $4.80M 10-Q · filed 2024-01-03 | $52.63M derived: sum of 2 quarters · filed 2024-01-03 | -$10.24M 10-Q · filed 2024-01-03 | -$14.28M derived: sum of 4 quarters · filed 2024-01-03 | |
| 2022-06-30 | $47.83M 10-Q · filed 2024-01-03 | -$15.04M 10-Q · filed 2023-08-14 | -$19.08M derived: sum of 3 quarters · filed 2024-01-03 | $30.86M derived: sum of 4 quarters · filed 2024-01-03 | |
| 2022-03-31 | -$62.87M 10-Q · filed 2024-01-03 | -$66.91M derived: sum of 2 quarters · filed 2024-01-03 | -$16.97M derived: sum of 3 quarters · filed 2024-01-03 | -$81.45M derived: sum of 4 quarters · filed 2024-01-03 | |
| 2021-12-31 | -$4.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $45.90M derived: sum of 2 quarters · filed 2023-03-31 | -$18.58M derived: sum of 3 quarters · filed 2023-03-31 | -$100.12M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $49.94M 10-Q · filed 2022-11-10 | -$14.54M derived: sum of 2 quarters · filed 2022-11-10 | -$96.08M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | -$64.48M 10-Q · filed 2022-11-10 | -$7.13M 10-Q · filed 2021-08-19 | -$146.02M derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | -$81.54M 10-Q · filed 2022-11-10 | $38.03M 10-Q · filed 2021-08-19 | |||
| 2020-12-31 | -$208.23M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | -$46.33M 10-Q · filed 2021-11-12 | -$37.52K 10-Q · filed 2020-11-16 | -$181.94M derived: sum of 2 quarters · filed 2021-11-12 | -$212.14M derived: sum of 3 quarters · filed 2021-11-12 | |
| 2020-06-30 | -$135.62M 10-Q · filed 2021-11-12 | -$143.59K 10-Q · filed 2020-08-13 | -$165.82M derived: sum of 2 quarters · filed 2021-11-12 | ||
| 2020-03-31 | -$30.20M 10-Q · filed 2021-11-12 | $1.02M 10-Q · filed 2020-08-13 | |||
| 2019-09-30 | $1.12M 10-Q · filed 2020-11-16 | $1.76M derived: sum of 2 quarters · filed 2020-11-16 | $1.76M derived: sum of 3 quarters · filed 2020-11-16 | ||
| 2019-06-30 | $634.66K 10-Q · filed 2020-11-16 | $634.54K derived: sum of 2 quarters · filed 2020-11-16 | |||
| 2019-03-31 | -$121.00 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |